Roots Analysis has announced the
addition of
Presently, in silico tools / approaches are
available for the identification, selection and optimization of pharmacological
leads. in fact, the predictive power of such solutions has been demonstrated to
enable researchers to bypass the traditional experimental screening of billions
of molecules against hundreds of biological targets, thereby, allowing
significant reductions in the investment of both time and resources.
To order this 290+ page report, which features 120+ figures
and 130+ tables, please visit this
-https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html
Key Market Insights
Over 90 players
currently claim to provide in silico drug discovery services for biologics
More than 70% of
these companies are small and mid-sized firms. Further, close to 60% of the CROs
engaged in this domain, claim to provide services to both pharmaceutical
companies and academic institutes. It is worth mentioning that about 30% of players
presently offer end-to-end drug discovery services
Over 150 software
solutions are currently available for use in drug discovery
Around 90 companies are
currently providing software tools, web applications and other technology
platforms for drug discovery. Examples of popular softwares include (in
alphabetical order) FORECASTER SUITE, MOPAC2016™, PKPlus™, REAL Space Navigator,
SaaS Platform and VolSurf+.
This can be
attributed to the relatively high adoption of the in silico approach by players
based in Europe and North America. On the other hand, there are companies that
are using this approach for drug discovery operations, in emerging regions,
such as India and China, as well.
Around 40% of the companies claim to specialize in antibodies, proteins and peptides
Within the antibodies
segment, nearly 60% of in silico service offerings are focused on the discovery
of monoclonal antibodies. This is followed by companies providing services for antibody
fragments (43%), bispecific antibodies (34%) and polyclonal antibodies (26%).
Using in silico
solutions / tools is estimated to save ~35% of the overall
drug discovery cost
By 2030, we
anticipate net, annual cost savings of over USD 23 billion to be brought about
by the adoption of in silico tools in large molecule drug discovery
processes. The computation approach also enables researchers to expedite the
overall process, thereby, saving a significant amount of time, as well.
North America and
Europe are anticipated to capture over 75% of the market share by 2030
Within
North America, US is anticipated to hold the 90% of the market share. It is
worth mentioning that the market in Asia-Pacific region is anticipated to grow
at a relatively faster rate (16.1%).
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/298/request-sample.html
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
2.
3.
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
